Trial Profile
Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. CHIP trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ISA 102 (Primary) ; Gemcitabine; Peginterferon alfa-2b
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CHIP
- 16 Jul 2012 New source identified and integrated (ClinicalTrials.gov record NCT01639885).
- 25 Jun 2011 New trial record